These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 31051172)

  • 1. Near-Neighbor Interactions in the NS3-4A Protease of HCV Impact Replicative Fitness of Drug-Resistant Viral Variants.
    Doncheva NT; Domingues FS; McGivern DR; Shimakami T; Zeuzem S; Lengauer T; Lange CM; Albrecht M; Welsch C
    J Mol Biol; 2019 May; 431(12):2354-2368. PubMed ID: 31051172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended interaction networks with HCV protease NS3-4A substrates explain the lack of adaptive capability against protease inhibitors.
    Dultz G; Shimakami T; Schneider M; Murai K; Yamane D; Marion A; Zeitler TM; Stross C; Grimm C; Richter RM; Bäumer K; Yi M; Biondi RM; Zeuzem S; Tampé R; Antes I; Lange CM; Welsch C
    J Biol Chem; 2020 Oct; 295(40):13862-13874. PubMed ID: 32747444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus.
    Shimakami T; Welsch C; Yamane D; McGivern DR; Yi M; Zeuzem S; Lemon SM
    Gastroenterology; 2011 Feb; 140(2):667-75. PubMed ID: 21056040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape.
    Pham LV; Jensen SB; Fahnøe U; Pedersen MS; Tang Q; Ghanem L; Ramirez S; Humes D; Serre SBN; Schønning K; Bukh J; Gottwein JM
    J Hepatol; 2019 Mar; 70(3):388-397. PubMed ID: 30395912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptidomimetic escape mechanisms arise via genetic diversity in the ligand-binding site of the hepatitis C virus NS3/4A serine protease.
    Welsch C; Shimakami T; Hartmann C; Yang Y; Domingues FS; Lengauer T; Zeuzem S; Lemon SM
    Gastroenterology; 2012 Mar; 142(3):654-63. PubMed ID: 22155364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle.
    Serre SB; Jensen SB; Ghanem L; Humes DG; Ramirez S; Li YP; Krarup H; Bukh J; Gottwein JM
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3563-78. PubMed ID: 27021330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ketoamide resistance and hepatitis C virus fitness in val55 variants of the NS3 serine protease.
    Welsch C; Schweizer S; Shimakami T; Domingues FS; Kim S; Lemon SM; Antes I
    Antimicrob Agents Chemother; 2012 Apr; 56(4):1907-15. PubMed ID: 22252823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational study on the drug resistance mechanism against HCV NS3/4A protease inhibitors vaniprevir and MK-5172 by the combination use of molecular dynamics simulation, residue interaction network, and substrate envelope analysis.
    Xue W; Ban Y; Liu H; Yao X
    J Chem Inf Model; 2014 Feb; 54(2):621-33. PubMed ID: 23745769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural HCV variants with increased replicative fitness due to NS3 helicase mutations in the C-terminal helix α18.
    Stross C; Shimakami T; Haselow K; Ahmad MQ; Zeuzem S; Lange CM; Welsch C
    Sci Rep; 2016 Jan; 6():19526. PubMed ID: 26787124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study of the efficiency of HCV NS3/4A protease drugs against different HCV genotypes using in silico approaches.
    Ezat AA; Elshemey WM
    Life Sci; 2019 Jan; 217():176-184. PubMed ID: 30528183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphisms associated with resistance to protease inhibitors in naïve patients infected with hepatitis C virus genotype 1 in Argentina: Low prevalence of Q80K.
    Martínez AP; Culasso ACA; Pérez PS; Romano V; Campos RH; Ridruejo E; García G; Di Lello FA
    Virus Res; 2017 Aug; 240():140-146. PubMed ID: 28837817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease.
    Zhou Y; Bartels DJ; Hanzelka BL; Müh U; Wei Y; Chu HM; Tigges AM; Brennan DL; Rao BG; Swenson L; Kwong AD; Lin C
    Antimicrob Agents Chemother; 2008 Jan; 52(1):110-20. PubMed ID: 17938182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular characterization of hepatitis C virus for determination of subtypes and detection of resistance mutations to protease inhibitors in a group of intravenous drug users co-infected with HIV.
    Silva T; Cortes Martins H; Coutinho R; Leitão E; Silva R; Pádua E
    J Med Virol; 2015 Sep; 87(9):1549-57. PubMed ID: 25940586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance outside the substrate envelope: hepatitis C NS3/4A protease inhibitors.
    Özen A; Prachanronarong K; Matthew AN; Soumana DI; Schiffer CA
    Crit Rev Biochem Mol Biol; 2019 Feb; 54(1):11-26. PubMed ID: 30821513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic background for development of resistance mutations within the HCV NS3 protease-helicase in direct acting antiviral naive patients.
    Grammatikos G; Jabara CB; Ahmad MQ; Herrmann E; Zeuzem S; Welsch C
    Antivir Ther; 2014; 19(5):455-61. PubMed ID: 24457994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacophore-Assisted Covalent Docking Identifies a Potential Covalent Inhibitor for Drug-Resistant Genotype 3 Variants of Hepatitis C Viral NS3/4A Serine Protease.
    Iman K; Mirza MU; Sadia F; Froeyen M; Trant JF; Chaudhary SU
    Viruses; 2024 Aug; 16(8):. PubMed ID: 39205224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epistatic interactions promote persistence of NS3-Q80K in HCV infection by compensating for protein folding instability.
    Dultz G; Srikakulam SK; Konetschnik M; Shimakami T; Doncheva NT; Dietz J; Sarrazin C; Biondi RM; Zeuzem S; Tampé R; Kalinina OV; Welsch C
    J Biol Chem; 2021 Sep; 297(3):101031. PubMed ID: 34339738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low susceptibility of asunaprevir towards R155K and D168A point mutations in HCV NS3/4A protease: A molecular dynamics simulation.
    Kammarabutr J; Mahalapbutr P; Nutho B; Kungwan N; Rungrotmongkol T
    J Mol Graph Model; 2019 Jun; 89():122-130. PubMed ID: 30884449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of naturally occurring amino acid substitutions associated with resistance to hepatitis C virus NS3/NS4A protease inhibitors in São Paulo state.
    Moreira RC; de Torres Santos AP; Lisboa-Neto G; Mendes-Corrêa MCJ; Lemos MF; Malta FM; Santana RAF; Dastoli GTF; de Castro VFD; Pinho JRR
    Arch Virol; 2018 Oct; 163(10):2757-2764. PubMed ID: 29961118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
    López-Labrador FX; Moya A; Gonzàlez-Candelas F
    Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.